Inhibikase Therapeutics Inc (IKT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $213.21M
Last updated: Nov 17, 2026 at 11:06 AM ET
Inhibikase Therapeutics Inc (IKT) Competitors
The companies most similar to Inhibikase Therapeutics are Inovio Pharmaceuticals (INO), Bicycle Therapeutics (BCYC) and Bright Minds Biosciences (DRUG). By market cap, Inhibikase Therapeutics ranks 5th of the 13 companies on this page; Prelude Therapeutics (PRLD) is the largest at $275.32M.
Peer Comparison
IKT's revenue growth of -100.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics (IKT) | $213.21M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Inovio Pharmaceuticals Inc (INO) | $267.85M | N/A | 462.0x | 0.0% | N/A | -100.0% | 0.00% |
| Bicycle Therapeutics Ltd (BCYC) | $236.22M | N/A | 2.7x | -169.8% | N/A | 190.2% | 0.00% |
| Bright Minds Biosciences Inc (DRUG) | $227.96M | N/A | N/A | 0.0% | -11.2% | 0.0% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| InflaRx N.V. (IFRX) | $172.42M | N/A | N/A | 0.0% | N/A | -80.8% | 0.00% |
| Keros Therapeutics Inc (KROS) | $202.13M | N/A | 4.9x | -151.4% | N/A | 180.5% | 0.00% |
| Sionna Therapeutics, Inc. Common Stock (SION) | $150.63M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Prelude Therapeutics Inc (PRLD) | $275.32M | N/A | 16.3x | -269.7% | N/A | 41.0% | 0.00% |
| Whitehawk Therapeutics, Inc. (WHWK) | $180.57M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Eledon Pharmaceuticals Inc (ELDN) | $178.63M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Upstream Bio, Inc. (UPB) | $152.38M | N/A | 41.0x | 0.0% | N/A | -42.2% | 0.00% |
| Pyxis Oncology Inc (PYXS) | $188.98M | N/A | 11.6x | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $184.77M | N/A | 11.6x | 0.0% | -11.2% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Inhibikase Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Inovio Pharmaceuticals Inc (INO) | Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development... | INO competitors |
| Bicycle Therapeutics Ltd (BCYC) | Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. | BCYC competitors |
| Bright Minds Biosciences Inc (DRUG) | Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies... | DRUG competitors |
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| InflaRx N.V. (IFRX) | InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. | IFRX competitors |
| Keros Therapeutics Inc (KROS) | Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery... | KROS competitors |
| Sionna Therapeutics, Inc. Common Stock (SION) | Sionna Therapeutics, Inc. is an innovative biotechnology company focused on developing advanced therapies for neurodegenerative disorders... | SION competitors |
| Prelude Therapeutics Inc (PRLD) | Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized... | PRLD competitors |
| Whitehawk Therapeutics, Inc. (WHWK) | Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. | WHWK competitors |
| Eledon Pharmaceuticals Inc (ELDN) | Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases... | ELDN competitors |
| Upstream Bio, Inc. (UPB) | Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. | UPB competitors |
| Pyxis Oncology Inc (PYXS) | Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)... | PYXS competitors |
Frequently Asked Questions About IKT
Who are Inhibikase Therapeutics' main competitors?
The companies most similar to Inhibikase Therapeutics include Inovio Pharmaceuticals (INO), Bicycle Therapeutics (BCYC), Bright Minds Biosciences (DRUG), Invivyd (IVVD) and InflaRx (IFRX), listed from the closest match.
Who is Inhibikase Therapeutics' biggest competitor?
Prelude Therapeutics (PRLD) is the largest of the similar companies at $275.32M; Inovio Pharmaceuticals (INO) is the closest match by business profile, size, sector and industry.
How does IKT stock compare with its competitors?
IKT's net margin is 0.0% against a peer median of 0.0%.
Which of Inhibikase Therapeutics' competitors pays a higher dividend?
Inhibikase Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Inhibikase Therapeutics bigger than its competitors?
No. Inhibikase Therapeutics is 5th by market cap among the 13 companies on this page; the largest is Prelude Therapeutics (PRLD) at $275.32M.
IKT pages: Overview, Earnings, Forecast, Financials, Competitors